Marijuana Studies and

Cannabis Research

09/27/2018
Author(s): D.M. Kerr, L. Downeya, M. Conboya, D.P. Finnb, M. Rochea. Prenatal exposure to valproic acid is associated with alterations in the endocannabinoid system of the brain. These results indicate that it is possible that endocannabinoid dysfunction may be the basis of behavioral abnormalities observed in autism spectrum disorders. View study
09/27/2018
Author(s): Csaba Földy, Robert C. Malenka, and Thomas C. Südhof. Neuroligin-3 is specifically necessary for tonic endocannabinoid signaling. This suggests that alterations in endocannabinoid signaling may contribute to the pathophysiology of autism. View study
09/27/2018
Author(s): Miriam Schneider, and Michael Koch. The medial prefrontal cortex (mPFC) contributes to the development of social behavior skills of adults, social motivation and personal hygiene. In addition, the results of this study suggest that the cannabinoid system has participation in anxiety and social behavior. View study
09/27/2018
Author(s): Q.-R. Liu†, C.-H. Pan†,∞, A. Hishimoto†, C.-Y. Li†, Z.-X. Xi‡, A. Llorente-Berzal§, M.-P. Viveros§, H. Ishiguro†,¶, T. Arinami¶, E. S. Onaivi∗ ,†,∗∗ and G. R. Uhl†. The results of this study suggest that the cannabinoid CB2-R could be involved in the mechanisms of endocannabinoid signaling associated with the regulation of emotionality. More studies are needed to determine if the CB2-R ligands increase the risk of depression or suicide (which led to the recall of Rimonabant as an appetite suppressant in the control of obesity). View study
09/27/2018
Author(s): Q.-R. Liu†, C.-H. Pan†,∞, A. Hishimoto†, C.-Y. Li†, Z.-X. Xi‡, A. Llorente-Berzal§, M.-P. Viveros§, H. Ishiguro†,¶, T. Arinami¶, E. S. Onaivi∗ ,†,∗∗ and G. R. Uhl†. The results of this study suggest that the cannabinoid CB2-R could be involved in the mechanisms of endocannabinoid signaling associated with the regulation of emotionality. More studies are needed to determine if the CB2-R ligands increase the risk of depression or suicide (which led to the recall of Rimonabant as an appetite suppressant in the control of obesity). View study
09/27/2018
Author(s): René Kurz, Kurt Blaas. In assessing the effectiveness of dronabinol as a complementary therapy in a child with autistic disorder, it was found that dronabinol can reduce the symptoms of autism. View study
09/27/2018
Author(s): Kwang-Mook Jung1, *, Marja Sepers2,3, *, Christopher M. Henstridge4, *, Olivier Lassalle5,6,7, Daniela Neuhofer5,6,7, Henry Martin5,6,7, Melanie Ginger2,3, Andreas Frick2,3, Nicholas V. DiPatrizio1 , Ken Mackie8, Istvan Katona4, Daniele Piomelli1,9,10 & Olivier J. Manzoni2,3. The pharmacological potentiation of 2-arachidonoyl-sn-glycerol signaling normalizes the synaptic defect of depression and corrects behavioral abnormalities in mice with fragile X syndrome. The endocannabinoid signalosome is a molecular substrate for fragile X syndrome, which might be targeted by therapy. View study
09/27/2018
Author(s): Bhismadev Chakrabarti1,2* and Simon Baron-Cohen2. CNR1 modulates striatal function through which social reward signals are perceived, such as happy faces. These results suggest that CNR1 is a key element in the perception process of certain basic emotions. View study
09/27/2018
Author(s): M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza. This study results highlight the anti-inflammatory effects of cannabidiol in this viral model of multiple sclerosis and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component. View study
09/27/2018
Author(s): Lourdes Ruiz-Valdepeñas, José A Martínez-Orgado, Cristina Benito, África Millán, Rosa M Tolón,Julián Romero. CBD exhibits antioxidant and anti-inflammatory properties. These data highlight the anti-inflammatory and vascular stabilizing effects of CBD in endotoxic shock and suggest a possible beneficial effect of this natural cannabinoid. View study
09/27/2018
Author(s): Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, Simona Pisanti, Luciano De Petrocellis, Chiara Laezza, Giuseppe Portella, Maurizio Bifulco, and Vincenzo Di Marzo. A comparison of antitumor properties of different cannabinoids. The results obtained show that cannabidiol is the most potent inhibitor of the growth of cancer cells. View study
09/27/2018
Author(s): Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia, and Pierre-Yves Desprez. CBD would help treat breast cancer since it can significantly decrease the development of metastatic cells. View study
09/27/2018
Author(s): Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, and Anil Prasad. CBD induced both apoptosis and death induced by autophagy in breast cancer cells. View study
09/27/2018
Author(s): María M. Caffarel, Clara Andradas, Eduardo Pérez-Gómez, Manuel Guzmán, Cristina Sánchez. Cannabinoid-based drugs may be useful for the treatment of most subtypes of mammary tumors. View study
09/27/2018
Author(s): María M Caffarel1,6, Clara Andradas1 , Emilia Mira2 , Eduardo Pérez-Gómez1 , Camilla Cerutti1,6, Gema Moreno-Bueno3 , Juana M Flores4 , Isabel García-Real4 , José Palacios5 , Santos Mañes2 , Manuel Guzmán1 , Cristina Sánchez. Preclinical evidence indicating the possible efficacy of the use of cannabidoids in the treatment of ErbB2-positive breast cancer, characterized by highly aggressive phenotypes and a reduced response to standard therapies. View study
09/27/2018
Author(s): Lesley A Smith, Fredric Azariah, Verna TC Lavender, Nicola S Stoner, Silvana Bettiol. Conventional anti-cancer drugs do not always work for everyone, and can cause nausea and vomiting. Therefore, therapeutic THC-based drugs (Cannabis) have already been approved for use in some countries. View study
09/27/2018
Author(s): Simona Pisanti, Cristina Borselli, Olimpia Oliviero, Chiara Laezza, Patrizia Gazzero, and Maurizio Bifulco. Anandamide is potentially involved in the control of cancer growth directed both to the proliferation of tumor cells and to the angiogenic stimulation of the vasculature. View study
09/27/2018
Author(s): G. Velasco; C. Sánchez and M. Guzmán. There is a lot of evidence that shows how cannabinoids can reduce cancer tumors in animals. These findings already serve as the basis for the development of studies that analyze the therapeutic potential of cannabinoids to fight cancer. View study
09/27/2018
Author(s): CHENGZHI XIE, GUOXING LIU, JIEFENG LIU, ZHAO HUANG, FUSHENG WANG, XIAOHUA LEI, XIAOLONG WU, SHENGFU HUANG, DEWU ZHONG and XUNDI XU. A study demonstrating that endogenous cannabinoid anandamide AEA inhibits the proliferation of cancer cells and induces cellular apoptosis, suggesting its therapeutic potential in the treatment of patients with human hepatocellular carcinoma. View study
09/27/2018
Author(s): ISMAEL GALVE-ROPERH, CRISTINA SÁNCHEZ , MARÍA LUISA CORTÉS , TERESA GÓMEZ DEL PULGAR , MARTA IZQUIERDO & MANUEL GUZMÁN. THC (the main component of cannabis) induces apoptosis (cell death) of cancer cells in culture. Its intratumoral administration induced a considerable regression of malignant gliomas. View study
09/27/2018
Author(s): D. Vara , M. Salazar, N. Olea-Herrero, M. Guzmán, G. Velasco, and I Díaz-Laviada. Findings that reveal the therapeutic potential of cannabinoids for the treatment of hepatocellular carcinoma, especially in advanced stages. View study
09/27/2018
Author(s): Nadine Freimuth, Robert Ramer, and Burkhard Hinz. Cannabinoids may likewise affect cancer cell angiogenesis, migration, invasion, adhesion, and metastasization. View study
09/27/2018
Author(s): M. Guzmán, M.J. Duarte , C. Blázquez , J. Ravina, M.C. Rosa, I. Galve-Roperh , C. Sánchez , G. Velasco and L. González-Feria. Due to its ability to inhibit tumor growth in animals, THC and other cannabinoids have been suggested as antitumor drugs. This is the first clinical study to test the application of THC in human patients with recurrent glioblastoma multiforme. The results demonstrate the safety profile of THC and its action on tumor cells, which establishes the basis for future trials. View study
09/27/2018
Author(s): Natalya M. Kogan, Cristina Blazquez, Luis ´ Alvarez, Ruth Gallily, Michael Schlesinger, ´ Manuel Guzman, and Raphael Mechoulam. Cannabidiol hydroxyquinone (HU-331) has a great potential to become an antiangiogenic and anticancer drug. This study demonstrated that HU-331 was able to significantly inhibit angiogenesis at very low concentrations, in addition to significantly decreasing the total area occupied by the vessels in the treated tumors. View study